The branded generics market size has grown strongly in recent years. It will grow from $335.98 billion in 2023 to $367.67 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. Historical growth was driven by factors such as cost efficiencies, patent expirations, market reach expansion, government-driven initiatives, and healthcare policy reforms.
The branded generics market size is expected to see rapid growth in the next few years. It will grow to $542.32 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. Anticipated growth in the upcoming period is linked to heightened demand for generic biologics, the increasing prevalence of chronic illnesses, expanding markets in emerging economies, and a dedicated emphasis on biosimilar products. Key trends expected in this forecast period comprise strategic partnerships and collaborations, technological advancements, a concentrated focus on chronic disease management, market consolidation, and a strong commitment to a patient-centric approach.
The burgeoning prevalence of chronic diseases is anticipated to fuel the expansion of the branded generics market. These enduring ailments, often incurable but manageable, are on the rise due to factors such as tobacco use, poor dietary habits, sedentary lifestyles, and excessive alcohol consumption. The global populace increasingly favors branded generics for treating chronic conditions, attracted by their cost-effectiveness compared to standard medications. Highlighting this trend, in September 2022, the World Health Organization (WHO) reported 41 million deaths worldwide, representing 74% of all noncommunicable disease (NCD) fatalities annually. This upsurge in chronic diseases is poised to elevate the demand for branded generics in the foreseeable future.
The escalating need within the pharmaceutical sector is set to propel the ascent of the branded generics market. This industry, dedicated to drug research, development, production, and marketing for medical purposes, leans on branded generics as an economical alternative to branded drugs. Additionally, these generics help sustain patient loyalty by offering a familiar, trusted product, even when the formulation is available as a generic. Notably, as per the European Federation of Pharmaceutical Industries and Associations (EFPIA) in June 2023, the pharmaceutical production in Europe reached $384,200 million (€340,000 million) in 2022, marking a 4.95% increase from the previous year. This surge in pharmaceutical demand underpins the growth of the branded generics market.
In December 2021 witnessed Biocon Ltd., an India-based biopharmaceutical entity, forging a strategic alliance with Tabuk Pharmaceuticals. This collaboration marks Biocon's foray into the MENA region encompassing Jordan, Lebanon, Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, and Iraq. The intent behind this partnership is to curate an extensive global product portfolio aimed at providing cost-effective treatments to patients worldwide. Tabuk Pharmaceuticals, rooted in Saudi Arabia, will take charge of marketing authorization, registration, importation, and promotion of these medications within Saudi Arabia and adjoining Middle Eastern countries.
In June 2022, Dr. Reddy's Laboratories, a prominent Indian pharmaceutical firm specializing in branded generics, completed the acquisition of branded and generic injectable products from Eton Pharmaceuticals, Inc., a US-based pharmaceutical company. This transaction, valued at $50 million, serves Dr. Reddy's Laboratories' strategic agenda to expedite and broaden the availability of affordable medications. The acquisition includes notable products such as Biorphen (phenylephrine hydrochloride) injection and Rezipres, augmenting their efforts to introduce biosimilars into the market.
In July 2021, Lupin, an India-based pharmaceutical company offering branded and generic formulations, biosimilars, and active pharmaceutical ingredients (APIs), acquired Southern Cross Pharma Pvt Ltd (SCP) for an undisclosed amount. Through this acquisition, Generic Health, an Australia-based wholly-owned subsidiary of global pharma major Lupin Limited, will have access to more than 60 registered products with approximately USD 22 million in sales. It will result in the growth of value offer and market share of Lupin in the Australian market. Southern Cross Pharma Pvt Ltd (SCP) is an Australia-based pharmaceutical company engaged in developing, registering, and distributing generic products.
Major companies operating in the branded generics market report are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International PLC, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.
North America was the largest region in the branded generics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the branded generics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Branded generics encompass several drug classes, such as alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid-lowering drugs, anti-depressants, anti-psychotics, anti-epileptics, and others. Alkylating agents within branded generics are a subset of anticancer medications that impede DNA-to-RNA conversion, effectively disrupting protein synthesis. These chemicals modify hydrogen atoms on DNA to alkyl groups, inducing cross-links within the DNA strand, leading to cytotoxic, mutagenic, and carcinogenic effects. Branded generics offer various administration routes including topical, oral, parenteral, and others. They cater to diverse medical conditions encompassing oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal ailments, dermatological conditions, analgesics, anti-inflammatory treatments, and more.
The branded generics market research report is one of a series of new reports that provides branded generics market statistics, including branded generics industry global market size, regional shares, competitors with a branded generics market share, detailed branded generics market segments, market trends and opportunities, and any further data you may need to thrive in the branded generics industry. This branded generic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The branded generics market consists of sales of glucophage, lopressor, and trimox. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The branded generics market size is expected to see rapid growth in the next few years. It will grow to $542.32 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. Anticipated growth in the upcoming period is linked to heightened demand for generic biologics, the increasing prevalence of chronic illnesses, expanding markets in emerging economies, and a dedicated emphasis on biosimilar products. Key trends expected in this forecast period comprise strategic partnerships and collaborations, technological advancements, a concentrated focus on chronic disease management, market consolidation, and a strong commitment to a patient-centric approach.
The burgeoning prevalence of chronic diseases is anticipated to fuel the expansion of the branded generics market. These enduring ailments, often incurable but manageable, are on the rise due to factors such as tobacco use, poor dietary habits, sedentary lifestyles, and excessive alcohol consumption. The global populace increasingly favors branded generics for treating chronic conditions, attracted by their cost-effectiveness compared to standard medications. Highlighting this trend, in September 2022, the World Health Organization (WHO) reported 41 million deaths worldwide, representing 74% of all noncommunicable disease (NCD) fatalities annually. This upsurge in chronic diseases is poised to elevate the demand for branded generics in the foreseeable future.
The escalating need within the pharmaceutical sector is set to propel the ascent of the branded generics market. This industry, dedicated to drug research, development, production, and marketing for medical purposes, leans on branded generics as an economical alternative to branded drugs. Additionally, these generics help sustain patient loyalty by offering a familiar, trusted product, even when the formulation is available as a generic. Notably, as per the European Federation of Pharmaceutical Industries and Associations (EFPIA) in June 2023, the pharmaceutical production in Europe reached $384,200 million (€340,000 million) in 2022, marking a 4.95% increase from the previous year. This surge in pharmaceutical demand underpins the growth of the branded generics market.
In December 2021 witnessed Biocon Ltd., an India-based biopharmaceutical entity, forging a strategic alliance with Tabuk Pharmaceuticals. This collaboration marks Biocon's foray into the MENA region encompassing Jordan, Lebanon, Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, and Iraq. The intent behind this partnership is to curate an extensive global product portfolio aimed at providing cost-effective treatments to patients worldwide. Tabuk Pharmaceuticals, rooted in Saudi Arabia, will take charge of marketing authorization, registration, importation, and promotion of these medications within Saudi Arabia and adjoining Middle Eastern countries.
In June 2022, Dr. Reddy's Laboratories, a prominent Indian pharmaceutical firm specializing in branded generics, completed the acquisition of branded and generic injectable products from Eton Pharmaceuticals, Inc., a US-based pharmaceutical company. This transaction, valued at $50 million, serves Dr. Reddy's Laboratories' strategic agenda to expedite and broaden the availability of affordable medications. The acquisition includes notable products such as Biorphen (phenylephrine hydrochloride) injection and Rezipres, augmenting their efforts to introduce biosimilars into the market.
In July 2021, Lupin, an India-based pharmaceutical company offering branded and generic formulations, biosimilars, and active pharmaceutical ingredients (APIs), acquired Southern Cross Pharma Pvt Ltd (SCP) for an undisclosed amount. Through this acquisition, Generic Health, an Australia-based wholly-owned subsidiary of global pharma major Lupin Limited, will have access to more than 60 registered products with approximately USD 22 million in sales. It will result in the growth of value offer and market share of Lupin in the Australian market. Southern Cross Pharma Pvt Ltd (SCP) is an Australia-based pharmaceutical company engaged in developing, registering, and distributing generic products.
Major companies operating in the branded generics market report are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International PLC, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.
North America was the largest region in the branded generics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the branded generics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Branded generics encompass several drug classes, such as alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid-lowering drugs, anti-depressants, anti-psychotics, anti-epileptics, and others. Alkylating agents within branded generics are a subset of anticancer medications that impede DNA-to-RNA conversion, effectively disrupting protein synthesis. These chemicals modify hydrogen atoms on DNA to alkyl groups, inducing cross-links within the DNA strand, leading to cytotoxic, mutagenic, and carcinogenic effects. Branded generics offer various administration routes including topical, oral, parenteral, and others. They cater to diverse medical conditions encompassing oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal ailments, dermatological conditions, analgesics, anti-inflammatory treatments, and more.
The branded generics market research report is one of a series of new reports that provides branded generics market statistics, including branded generics industry global market size, regional shares, competitors with a branded generics market share, detailed branded generics market segments, market trends and opportunities, and any further data you may need to thrive in the branded generics industry. This branded generic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The branded generics market consists of sales of glucophage, lopressor, and trimox. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Branded Generics Market Characteristics3. Branded Generics Market Trends and Strategies32. Global Branded Generics Market Competitive Benchmarking33. Global Branded Generics Market Competitive Dashboard34. Key Mergers and Acquisitions in the Branded Generics Market
4. Branded Generics Market - Macro Economic Scenario
5. Global Branded Generics Market Size and Growth
6. Branded Generics Market Segmentation
7. Branded Generics Market Regional and Country Analysis
8. Asia-Pacific Branded Generics Market
9. China Branded Generics Market
10. India Branded Generics Market
11. Japan Branded Generics Market
12. Australia Branded Generics Market
13. Indonesia Branded Generics Market
14. South Korea Branded Generics Market
15. Western Europe Branded Generics Market
16. UK Branded Generics Market
17. Germany Branded Generics Market
18. France Branded Generics Market
19. Italy Branded Generics Market
20. Spain Branded Generics Market
21. Eastern Europe Branded Generics Market
22. Russia Branded Generics Market
23. North America Branded Generics Market
24. USA Branded Generics Market
25. Canada Branded Generics Market
26. South America Branded Generics Market
27. Brazil Branded Generics Market
28. Middle East Branded Generics Market
29. Africa Branded Generics Market
30. Branded Generics Market Competitive Landscape and Company Profiles
31. Branded Generics Market Other Major and Innovative Companies
35. Branded Generics Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Branded Generics Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on branded generics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for branded generics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Drug Class: Alkylating Agents; Antimetabolites; Hormones; Anti-hypertensive; Lipid Lowering Drugs; Anti-depressants; Anti-psychotics; Anti-Epileptics; Other Drugs
2) By Route of Administration: Topical; Oral; Parenteral; Other Routes of Administration
3) By Application: Oncology; Cardiovascular Diseases; Diabetes; Neurology; Gastrointestinal Diseases; Dermatology Diseases; Analgesics and Anti-inflammatory; Other Applications
Key Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Sanofi SA; AstraZeneca plc; GlaxoSmithKline plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Pfizer Inc.
- F. Hoffmann-La Roche AG
- Sanofi SA
- AstraZeneca plc
- GlaxoSmithKline plc
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Alkem Laboratories Ltd.
- Mylan N.V.
- Sandoz International GmbH
- Bausch Health Companies Inc.
- Sun Pharmaceutical Industries Ltd.
- Cipla Ltd.
- Aurobindo Pharma Ltd.
- Dr. Reddy's Laboratories Ltd.
- Apotex Inc.
- Aspen Pharmacare Holdings Limited
- Endo International plc
- Towa Pharmaceutical Co. Ltd.
- Mankind Pharma
- Glenmark Pharmaceuticals
- Par Pharmaceuticals Inc.
- Unichem Laboratories Ltd.
- Torrent Pharmaceuticals Ltd.
- Wockhardt
- Intas Pharmaceuticals Ltd.
- Novartis International AG
- Novo Nordisk A/S
- Zydus Lifesciences Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 367.67 Billion |
| Forecasted Market Value ( USD | $ 542.32 Billion |
| Compound Annual Growth Rate | 10.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
